Immusoft Corporation
Latest round
- Series B
Last raised
- Jan 2019
Total raised
- $28M
Investors
- 8
About Immusoft Corporation
Immusoft Corporation specializes in innovative cell therapies that program B cells to produce therapeutic proteins.Immusoft specializes in innovative cell therapies that focus on programming B cells to produce therapeutic proteins, especially for patients suffering from rare diseases. Their core technology, Immune System Programming (ISP™), programs a patient's B cells to transform into plasma cells, which act as biofactories for therapeutic proteins.Immusoft generates revenue through partnerships and collaborations in the biotechnology sector, aimed at developing and commercializing proprietary cell therapy products. The company aims to expand its market presence in North America and Europe, with specific targets for new geographical regions by 2025. This strategy involves enhancing their flagship product ISP-001, which is crucial for their partnership-driven revenue model.
Who invested in Immusoft Corporation
8 investors across 4 rounds
See all investors in Immusoft Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immusoft Corporation
Who invested in Immusoft Corporation?
Immusoft Corporation has 8 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immusoft Corporation raised?
Immusoft Corporation has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Immusoft Corporation last raise money?
Immusoft Corporation's most recent round on record is a Series B, in Jan 2019.
What does Immusoft Corporation do?
Immusoft Corporation specializes in innovative cell therapies that program B cells to produce therapeutic proteins.
Where is Immusoft Corporation headquartered?
Immusoft Corporation is headquartered in Seattle, US.
Which VCs invest in companies like Immusoft Corporation?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immusoft Corporation's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immusoft Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.